Biotechnology China’s BeiGene and SpringWorks Therapeutics, have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) and SpringWorks’ investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors. 7 September 2018